What is ADMA Biologics's stock-based comp?

ADMA Biologics (ADMA) reported stock-based comp of $6.33M in Q1 2026.

How has ADMA Biologics's stock-based comp changed year-over-year?

ADMA Biologics's stock-based comp increased by 36.9% year-over-year, from $4.62M to $6.33M.

What is the long-term trend for ADMA Biologics's stock-based comp?

Over 4 years (2021 to 2025), ADMA Biologics's stock-based comp has grown at a 54.8% compound annual growth rate (CAGR), from $3.49M to $20.03M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

ADMA Biologics ADMA Stock-Based Comp

Stock-Based Comp at other companies

AbCellera Biologics Inc.ABCL

$12.01M-18.8%

AnaptysBio, Inc.ANAB

$14.22M+55.0%

ZymeworksZYME

$6.94M+8.3%

Apogee Therapeutics, Inc.APGE

$17.16M+54.2%

Quest DiagnosticsDGX

$20M-9.1%

BiohavenBHVN

$28.29M-46.7%

Segments

By segment

See full

Plasma Collection Centers$1.06M-17.4%

ADMA Bio Manufacturing$0—

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's stock-based comp?: ADMA Biologics (ADMA) reported stock-based comp of $6.33M in Q1 2026.
How has ADMA Biologics's stock-based comp changed year-over-year?: ADMA Biologics's stock-based comp increased by 36.9% year-over-year, from $4.62M to $6.33M.
What is the long-term trend for ADMA Biologics's stock-based comp?: Over 4 years (2021 to 2025), ADMA Biologics's stock-based comp has grown at a 54.8% compound annual growth rate (CAGR), from $3.49M to $20.03M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.